June 18, 2018

Clear To Resume IGNITE DMD

Dear Patient Community,

We’re pleased to share with you that the FDA has lifted the clinical hold on IGNITE DMD, our clinical trial investigating SGT-001 as a potential treatment for Duchenne muscular dystrophy (DMD). SGT-001 is a microdystrophin gene transfer candidate that we believe has the potential to slow or stop the progression of DMD, regardless of a patient’s genetic mutation, age or stage of condition. The FDA acknowledged Solid Biosciences satisfactorily addressed all of its clinical hold questions. We now have the green light to move forward with our clinical trial and continue to evaluate SGT-001’s potential in patients with DMD. We have already begun our activities to resume the study and are working to reinitiate enrollment as quickly as possible.

The FDA originally placed a hold on IGNITE DMD because the first patient dosed with SGT-001 in the clinical trial, a non-ambulatory adolescent, experienced a serious adverse event. Due to the excellent care of Dr. Barry Byrne and his team at the University of Florida, the event was identified early and well-managed. The event showed up in laboratory tests, and the patient had few symptoms throughout this experience. We are happy to share that the event has fully resolved and the young man has returned to his normal activities.

As a company directly touched by DMD, Solid Biosciences is always focused on patient safety. Based on what we have learned from the experience of this patient, we’ve made some modifications to the clinical trial protocol to help reduce the risk or impact of any potential future events. These changes include a modified steroid regimen and additional monitoring measures, as well as guides to facilitate early medical interventions should an event occur.

We also now plan to dose several children before dosing additional adolescents in the clinical trial. While this constitutes a change in the sequence of patients dosed with SGT-001, we have every intention to continue to evaluate SGT-001 in non-ambulatory adolescents as quickly as possible.

In addition, we have also made a change to the muscle biopsy schedule outlined in IGNITE DMD. Previously, our protocol stated that each patient enrolled would undergo three biopsies: one at baseline, one at 12 months and one intermediate biopsy at either three or six or nine months. Each patient will continue to undergo three biopsies; however, we now have added an option to take the intermediate biopsy at day 45 post administration. We believe that this additional time point will provide us with even more information to evaluate the potential efficacy of SGT-001.

We look forward to reviewing this information and answering questions during our presentation at the PPMD Annual Conference next week.

We recognize the decision to participate in clinical research is not made lightly, and we thank the patients and families who choose to do so. We will continue to do our best to minimize the burden of being in a clinical trial and to provide a positive patient experience.

We thank the entire DMD community for its continued support of our mission to make DMD a disease of the past and hope to see many of you at PPMD!

 

Sincerely,

Your Team at Solid Biosciences

Related news

Jun26

Ilan Ganot, Co-Founder and CEO, Assumes Additional Role of President
Gilad Hayeem, Co-Founder, President and Board Member, Retires to Pursue Other Activities

Jun18

- Activities to Resume Enrollment in IGNITE DMD Phase I/II Clinical Trial are Underway

- Conference Call Scheduled for Today at 8:30 A.M. ET

May19

- Data Reinforce Potential of SGT-001 as an Important Treatment Candidate for DMD -

- Company Continues to Advance Gene Therapy Portfolio -

May10
Company Finalizing Response to FDA Regarding Clinical Hold on SGT-001 Phase I/II Clinical Trial
Apr18

Letter to the Duchenne Community: Update on IGNITE DMD Clinical Trial

Apr18

- Full Clinical Hold Letter from the FDA Received; Company to Respond in the Coming Weeks -

- Manufacturing-related Partial Clinical Hold on the High Dose of SGT-001 Resolved -

Mar29

Solid Biosciences Inc. (NASDAQ:SLDB) today reported financial results for the full year ended December 31, 2017 and provided a corporate update.

Mar14

Today we announced that the U.S. Food and Drug Administration has placed our Phase I/II clinical trial for SGT-001, IGNITE DMD, on Clinical Hold following a serious adverse event that occurred in the first patient dosed, a non-ambulatory adolescent.

Mar14

Solid Biosciences Inc. (NASDAQ:SLDB) today announced it has received notification from the U.S. Food and Drug Administration ( FDA ) that IGNITE DMD, its Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD), has been placed on Clinical Hold.

Feb28

Solid Biosciences is proud to join the global rare disease community again this year to observe Rare Disease Day

Pages

More information about Solid?

Please subscribe to receive our latest news